BSX vs ZBH
BSX and ZBH side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BSXBOSTON SCIENTIFIC CORPORATION | ZBHZIMMER BIOMET HOLDINGS, INC. |
|---|---|---|
| Market cap | $67.87B | $19.26B |
| P/E (TTM) | 19.0 | 24.5 |
| P/B | 2.72 | 1.53 |
| P/S | 3.4x | 2.3x |
| Dividend yield | — | 0.99% |
| Revenue | $21.00B(TTM) | $8.51B(TTM) |
| Revenue growth (YoY) | 19.9% | 7.2% |
| Net income | $3.67B(TTM) | $806.70M(TTM) |
| Earnings growth (YoY) | 56.7% | -22.0% |
| EPS, diluted | $2.47(TTM) | $4.12(TTM) |
| EBIT margin | 18.0% | 13.3% |
| ROE | 11.6% | 5.6% |
| ROIC | 10.0% | 5.0% |
| Piotroski F | 8/9 | 6/9 |
| 1y total return | -55.7% | -3.0% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BSX vs ZBH
| Metric | BSX | ZBH |
|---|---|---|
| End value | $21.4K | $9.5K |
| Total return | +114.0% | -5.3% |
| CAGR | +7.6% | -0.5% |
| Volatility | 27.3% | 28.4% |
| Sharpe | 0.27 | -0.01 |
| Sortino | 0.36 | -0.02 |
| Max drawdown | -60.6% | -53.5% |
Based on 2600 common trading days, 2016-04-27 → 2026-08-28 · risk-free 3.9% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)